Abstract: 5-Azacytidine (5-Aza, Azacitidine) is a first-generation DNA hypomethylating agent (HMA) and cytidine analog that has become a cornerstone in the treatment of hematological malignancies, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). By incorporating into RNA and DNA, it irreversibly inhibits DNA methyltransferases (DNMTs), leading to DNA hypomethylation, reactivation of silenced tumor suppressor genes, and profound immune modulation. Despite its clinical efficacy, especially in older or medically unfit patients, the development of primary and secondary resistance remains a significant limitation, as the drug fails to completely eradicate leukemic stem cells. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, structural properties, limitations, and future perspectives of 5-Azacytidine. It highlights the emergence of oral formulations for maintenance therapy and novel combination strategies—most notably with the BCL-2 inhibitor venetoclax and other targeted agents—designed to overcome resistance and improve patient outcomes.
1. Introduction
5-Azacytidine (azacitidine) is a cytidine analog and epigenetic modifier that functions as a DNA hypomethylating agent (HMA) [1][6]. Originally developed in the 1960s as a conventional cytostatic therapy, it was later reintroduced at lower, repeated doses to exploit its hypomethylating potential without prohibitive toxicity [1]. It is approved by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes (MDS) and is broadly utilized for older, medically non-fit patients with acute myeloid leukemia (AML) [1][3]. The standard parenteral dosing schedule consists of 75 mg/m2 per day for seven days every 28 days [1][3]. Recently, an oral formulation of azacitidine (CC-486) has been developed and approved, offering the advantage of extended drug exposure and serving as an effective maintenance therapy for AML patients in first remission [1][4].
2. Pharmacological Activity
Azacitidine exhibits potent antileukemic activity by reducing clonal burden and improving hematopoiesis in MDS and AML [3]. It is particularly valuable for elderly patients or those with comorbidities who are ineligible for intensive chemotherapy [4][5]. Beyond monotherapy, azacitidine is highly active in combination regimens. The combination of azacitidine with the BCL-2 inhibitor venetoclax has revolutionized the treatment of older and unfit AML patients. In the VIALE-A phase 3 trial, this combination demonstrated significantly improved overall survival (14.7 months vs. 9.6 months with azacitidine alone) and higher composite complete remission rates [1][4][5]. Azacitidine is also being evaluated in combination with targeted therapies such as FLT3 inhibitors (e.g., gilteritinib) [8], IDH1/2 inhibitors (e.g., ivosidenib, enasidenib) [1], mutant p53 activators like APR-246 [1][7], and menin inhibitors (e.g., revumenib, bleximenib) for specific genetic subsets of AML [4][9]. Furthermore, the oral formulation CC-486 has shown efficacy as a maintenance therapy, significantly improving overall and relapse-free survival in older AML patients post-intensive chemotherapy [1][4].
3. Molecular Mechanism of Action
The mechanism of action of 5-azacytidine is multifaceted, involving cytotoxicity, epigenetic reprogramming, and immune modulation [3]. Upon cellular uptake via nucleoside transporters, azacitidine undergoes successive phosphorylation, with the first rate-limiting step catalyzed by uridine-cytidine kinase (UCK) [1]. As an S-phase-specific drug, it is incorporated into nucleic acids during replication. Unlike its derivative decitabine, which exclusively incorporates into DNA, only 10–20% of azacitidine is incorporated into DNA, while the vast majority (80–90%) incorporates into RNA [1].
Once incorporated into DNA, azacitidine is recognized by and irreversibly binds to DNA methyltransferase 1 (DNMT1), leading to the enzyme's proteasomal degradation [1][2]. This induces DNA hypomethylation, which reactivates aberrantly silenced tumor suppressor genes involved in apoptosis, DNA repair, and cell cycle regulation [1]. Additionally, azacitidine induces terminal differentiation of leukemic blasts by activating latent differentiation programs [2].
Extrinsic to the tumor cell, azacitidine exerts profound immunomodulatory effects. DNA demethylation leads to the reactivation of endogenous retroelements (EREs), which triggers an interferon response and viral mimicry, stimulating an innate immune reaction against the tumor [1][2]. Azacitidine also affects the bone marrow microenvironment by expanding regulatory T cells (Tregs), altering natural killer (NK) cell functionality, and upregulating immune checkpoint molecules like PD-1 and PD-L1 [1].
4. Structure-Activity Relationship (SAR)
5-Azacytidine is a synthetic analog of the naturally occurring nucleoside cytidine, characterized by the substitution of a carbon atom with a nitrogen atom at the 5-position of the pyrimidine ring [1]. This structural modification is critical for its mechanism: while it mimics cytidine closely enough to be incorporated into nucleic acids, the nitrogen at the 5-position prevents the covalent addition of a methyl group by DNMTs, instead trapping the enzyme in an irreversible covalent complex [1][2]. The presence of a hydroxyl group at the 2' position of the ribose sugar distinguishes azacitidine from its deoxy derivative, decitabine (5-aza-2'-deoxycytidine). This structural difference dictates that azacitidine is primarily incorporated into RNA, affecting RNA methylation and chromatin organization, whereas decitabine is strictly incorporated into DNA [1]. Furthermore, azacitidine is highly susceptible to rapid inactivation by the enzyme cytidine deaminase (CDA) in the gut and liver, resulting in a very short plasma half-life of approximately 35–40 minutes after subcutaneous or intravenous administration [1].
5. Current Limitations
Despite its efficacy, azacitidine therapy is limited by the inevitable development of primary and secondary resistance, as it fails to completely eradicate leukemic stem and progenitor cell populations [1][3]. Several intrinsic and extrinsic resistance mechanisms have been identified. Intrinsic factors include altered drug metabolism, such as low expression of UCK (impairing drug activation) or high levels of cytidine deaminase (CDA) (increasing drug degradation) [1]. Cell cycle quiescence, mediated by integrin α5 signaling, also confers resistance, as azacitidine requires active S-phase replication for incorporation [1]. Additionally, overexpression of the anti-apoptotic protein BCL2L10 and the expansion of resistant subclones contribute to treatment failure [1].
Extrinsic resistance mechanisms involve the tumor microenvironment, such as the failure to upregulate inflammation-related immune responses or the hypomethylation-induced upregulation of immune checkpoints (PD-1, PD-L1), which promotes immune evasion [1]. Furthermore, azacitidine is associated with significant myelosuppression, leading to cytopenias and an increased risk of opportunistic infections, which can necessitate dose reductions or treatment delays [3][5].
6. Future Perspectives
Future strategies aim to overcome resistance and enhance the efficacy of azacitidine through novel formulations and rational combination therapies. The development of oral azacitidine (CC-486) allows for extended dosing schedules (e.g., 14 or 21 days per 28-day cycle), sustaining DNA hypomethylation and providing a viable maintenance therapy option [1][4].
Combination therapies represent the most promising frontier. The synergy between azacitidine and venetoclax, which targets oxidative phosphorylation and eradicates leukemia stem cells, has already established a new standard of care [1][5]. Ongoing trials are exploring triplet regimens, adding agents like FLT3 inhibitors, IDH inhibitors, or menin inhibitors (e.g., revumenib, bleximenib) to the azacitidine/venetoclax backbone to target specific molecular vulnerabilities [1][4][9]. Additionally, combining azacitidine with immune checkpoint inhibitors (anti-PD-1/PD-L1) or macrophage checkpoint inhibitors (anti-CD47, magrolimab) aims to counteract HMA-induced immune evasion [1]. Finally, the identification of robust predictive biomarkers using machine learning and genomic profiling will be crucial for personalizing HMA-based therapies and maximizing patient benefit [1].
